Reuters reported that Bill Ackman’s Pershing Square and Pershing Square USA are set to list on the NYSE after Pershing Square USA raised $5 billion in its IPO. The debut marks Ackman’s renewed effort to bring a flagship U.S.-listed fund to market and tests investor appetite for closed-end funds. IPOX® Research Associate Lukas Muehlbauer was quoted on the offering’s structure, noting that shares of the managing company may have helped support investor demand beyond the fund alone in the listing.

Reuters reported that Rare Earths Americas launched its U.S. IPO roadshow, targeting a valuation of up to $368.4 million amid rising investor interest in critical minerals. The company plans to raise up to $52.8 million and list on NYSE American under “REA”. IPOX® Associate Lukas Muehlbauer was quoted, noting the company’s role in supply-chain diversification and the potential M&A appeal of newly public rare earth companies in a strategically important sector as global demand continues to accelerate sharply worldwide.

Lincoln International has filed for a rare U.S. initial public offering, joining the ranks of publicly traded boutique investment banks like Moelis and Houlihan Lokey. The Chicago-based firm, which reported $214.1 million in net income on $783.8 million in revenue for 2025, is capitalizing on a rebounding global dealmaking environment. IPOX® CEO Josef Schuster highlighted the asset class's resilience against recent geopolitical volatility, stating a "golden age for U.S. IPOs has arrived" amidst strong demand for U.S.-domiciled specialty deals.

Blackstone-backed mobile app marketing firm Liftoff has officially filed for a U.S. IPO on the Nasdaq under the ticker "LFTO." The company previously paused its listing plans amid market volatility but is now capitalizing on a broader rebound in technology stocks and easing geopolitical tensions. IPOX® Research Associate Lukas Muehlbauer provided expert commentary to Reuters, noting that Liftoff is strategically utilizing this reopening IPO window as investors view the recovering software space as increasingly attractive for new equity listings.

IPOX® Research Associate Lukas Muehlbauer was featured in a recent Reuters article discussing Kailera Therapeutics' $625 million IPO. As shares surged 62.5%, the debut signals a potential biotech IPO market turnaround. Muehlbauer highlighted the strong demand for GLP-1 companies, stating, "Obesity remains one of the few areas in biotech with clear investor appetite." He noted near-term trading relies heavily on broader obesity-drug space fundamentals.